UK-based Contract Research Organisation (CRO) Gentronix has received a King’s Award for Enterprise after achieving triple-figure revenue growth following rapid expansion in international markets.  

The toxicology specialist based at Alderley Park recorded total growth of 239% in overseas earning over the past three years. In the same period, the firm managed to raise its exported sales from 71% to 81%, driving revenue to over £10 million per annum. The US has been a particularly strong market for the firm with the region making up almost half of Gentronix’s international business.  

As a result of the success in overseas trading, Gentronix received a King’s Award for Enterprise for 2024. 

To support this growth, Gentronix has recently expanded laboratory space at its home at Alderley Park in Cheshire by 30 and increased its headcount to 67, with further investment continuing in 2024 and 2025. The company is currently supporting the needs of seven of the top 10 global pharmaceutical companies.  

CEO at Gentronix, Matt Tate, said: “The past three years have been extremely successful for the business as we continue on our long-term growth journey, and it has been especially satisfying to provide our services to new customers across the globe. We remain committed to offering best-in-class toxicology services to our expanding client base, whilst creating more opportunities for talented scientists in the North West, without whom we wouldn’t have been able to achieve any of this.”